Financial reports
20-F
2023 FY
Annual report (foreign)
13 Mar 24
20-F
2022 FY
Annual report (foreign)
29 Mar 23
20-F
2021 FY
Annual report (foreign)
29 Apr 22
20-F
2020 FY
Annual report (foreign)
24 Mar 21
20-F
2019 FY
Annual report (foreign)
31 Mar 20
20-F
2018 FY
Annual report (foreign)
28 Mar 19
20-F
2017 FY
Annual report (foreign)
30 Mar 18
20-F
2016 FY
Annual report (foreign)
31 Mar 17
20-F
2015 FY
Annual report (foreign)
31 Mar 16
20-F
2014 FY
Annual report (foreign)
22 Apr 15
Current reports
6-K
Current report (foreign)
23 Apr 24
6-K
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
19 Apr 24
6-K
ProQR Announces Year End 2023 Operating and Financial Results
13 Mar 24
6-K
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
15 Feb 24
6-K
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
19 Jan 24
6-K
Current report (foreign)
5 Jan 24
6-K
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
8 Dec 23
6-K
Current report (foreign)
7 Nov 23
6-K
ProQR Therapeutics Provides Update on Ophthalmic Assets
27 Sep 23
6-K
Current report (foreign)
3 Aug 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
24 Apr 23
RW
Registration withdrawal request
29 Mar 23
F-3
Shelf registration (foreign)
29 Mar 23
424B5
Prospectus supplement for primary offering
10 Mar 22
F-3
Shelf registration (foreign)
1 Mar 22
424B5
Prospectus supplement for primary offering
17 Nov 21
424B5
Prospectus supplement for primary offering
17 Nov 21
S-8
Registration of securities for employees
5 Nov 21
F-3
Shelf registration (foreign)
4 Nov 21
F-3
Shelf registration (foreign)
4 Nov 21
Proxies
No filings
Other
EFFECT
Notice of effectiveness
25 Apr 23
CORRESP
Correspondence with SEC
20 Apr 23
UPLOAD
Letter from SEC
4 Apr 23
EFFECT
Notice of effectiveness
10 Mar 22
CORRESP
Correspondence with SEC
7 Mar 22
UPLOAD
Letter from SEC
4 Mar 22
EFFECT
Notice of effectiveness
17 Nov 21
CORRESP
Correspondence with SEC
12 Nov 21
UPLOAD
Letter from SEC
10 Nov 21
EFFECT
Notice of effectiveness
21 Sep 20
Ownership
SC 13G/A
VAN HERK INVESTMENTS B.V.
14 Feb 24
SC 13G/A
VAN HERK INVESTMENTS B.V.
9 Feb 24
SC 13G
VAN HERK INVESTMENTS B.V.
14 Sep 23
SC 13G/A
RTW INVESTMENTS, LP
14 Feb 23
SC 13G/A
Stichting Aescap Life Sciences
9 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
9 Feb 23
SC 13G/A
GOLDMAN SACHS GROUP INC
8 Feb 23
SC 13G/A
ELI LILLY & Co
23 Dec 22
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
9 May 22